Welcome to this month's journal review podcast, covering key research from the Journal of the American Academy of Dermatology, July 2026 issue. Today we're focusing on a single article with direct relevance to prognostic counseling and surgical decision-making in melanoma patients. Let's get into it.

Our article is titled "Frailty and Survival Outcomes in Veterans with Invasive Cutaneous Melanoma: A Veterans Affairs Cancer Registry Retrospective Cohort Study," authored by Huhmann, Hwang, Kim, Nannini, Do, Gaziano, Wheless, Fillmore, and Hartman.

The clinical question here centers on whether frailty, as measured by the Veterans Affairs Frailty Index, predicts overall survival and melanoma-specific survival in veterans with invasive cutaneous melanoma. This matters because while frailty is an established prognostic variable across oncology broadly, prior work using the Veterans Affairs Frailty Index in melanoma populations focused on overall survival in patients receiving immune checkpoint inhibitors, without examining melanoma-specific mortality as a distinct outcome.

Study design: this is a retrospective cohort study drawing from the Veterans Affairs Cancer Registry, examining veterans with histologically confirmed invasive cutaneous melanoma diagnosed between 2009 and 2018. The final cohort included twelve thousand sixty-eight veterans. Frailty at the time of diagnosis was quantified using the Veterans Affairs Frailty Index, a deficit-accumulation index across thirty-one weighted health variables, yielding a score from zero, meaning no deficits, to one, meaning all deficits present. Patients were stratified into three groups: nonfrail, with a score of zero point two or below; mildly frail, between zero point two and zero point three; and moderate-to-severely frail, above zero point three. The cohort broke down as eighty-seven point nine percent nonfrail, eight point seven percent mildly frail, and three point four percent moderate-to-severely frail. Multivariable Cox proportional hazards models were stratified by stage—stage one and two versus stage three and four—and adjusted for age, sex, race, ethnicity, rurality, geographic region, histologic subtype, primary tumor site, and receipt of surgery.

Now to the key findings. For overall survival in stage one and two disease, frailty carried a substantial hazard. Mildly frail veterans had a hazard ratio of one point eight zero, with a ninety-five percent confidence interval of one point six four to one point nine eight, highly significant at P less than point zero zero one. Moderate-to-severely frail veterans fared worse still, with a hazard ratio of two point seven two, ninety-five percent confidence interval two point three nine to three point one zero, again P less than point zero zero one. However, when the outcome shifted to melanoma-specific survival in this same early-stage population, frailty showed no significant association. Mildly frail veterans had a hazard ratio of one point zero three, confidence interval zero point seven six to one point three nine, P equals point nine. Moderate-to-severely frail veterans actually trended toward a protective hazard ratio of zero point seven eight, confidence interval zero point four four to one point three nine, P equals point four, though this was not statistically significant.

In stage three and four disease, the pattern shifted somewhat. Overall survival remained strongly associated with frailty: mildly frail veterans had a hazard ratio of one point four four, confidence interval one point one nine to one point seven five, P less than point zero zero one; moderate-to-severely frail veterans had a hazard ratio of two point two six, confidence interval one point seven four to two point nine five, P less than point zero zero one. Critically, for melanoma-specific survival in advanced-stage disease, the moderate-to-severely frail group now showed a significant association, with a hazard ratio of one point five seven, confidence interval one point zero seven to two point three zero, P equals point zero two zero. The mildly frail group did not reach significance for melanoma-specific survival in this stage grouping, with a hazard ratio of one point two four, confidence interval zero point nine five to one point six zero, P equals point one one.

Across both stage groupings and both outcome types, surgery was consistently associated with improved survival. For overall survival, surgery carried a hazard ratio of zero point six zero in stage one and two disease and zero point four nine in stage three and four disease, both highly significant. For melanoma-specific survival, surgery's hazard ratio was zero point five two in early stage and zero point four one in advanced stage, both P less than point zero zero one or close to it.

The authors' interpretation is that frailty predicts worse overall survival across all melanoma stages, which is consistent with frailty functioning as a marker of competing mortality risk from non-melanoma causes. The dissociation between frailty and melanoma-specific survival in early-stage disease likely reflects the fact that melanoma-specific deaths are relatively uncommon in stage one and two, compared to the burden of other causes of death, in which frailty is a stronger driver. In stage three and four disease, however, where melanoma progression itself is the primary driver of mortality and systemic therapy plays a larger role, frailty becomes independently associated with disease-specific mortality, at least in the moderate-to-severely frail subgroup.

From a surgical practice standpoint, the takeaway is nuanced. Frailty assessment at diagnosis appears clinically useful for anticipating overall survival and informing shared decision-making around surgical candidacy and treatment intensity, particularly in early-stage melanoma where competing mortality from comorbidities may outweigh melanoma-specific risk. However, frailty should not be used in isolation to justify de-escalation of surgical management in early-stage disease based on assumed melanoma-specific risk, since this study found no significant association between frailty and melanoma-specific survival at that stage. In advanced-stage disease, moderate-to-severe frailty does carry independent melanoma-specific mortality risk, which may be relevant when weighing the aggressiveness of locoregional or systemic interventions. Across all strata, surgical intervention retained a strong independent association with improved survival, reinforcing that frailty alone should not automatically preclude surgical management.

Several limitations bear directly on how these results should be interpreted. This was a retrospective registry study, so residual confounding cannot be excluded. The dataset lacked information on systemic therapy exposure, which is a significant gap given that systemic treatment is central to outcomes in stage three and four disease and could confound the frailty-melanoma-specific survival association observed in that subgroup. The Veterans Affairs population is disproportionately male and older, limiting generalizability to broader dermatologic oncology populations. Frailty was assessed only once, at the time of diagnosis, so the analysis cannot capture how changes in frailty status over the disease course relate to outcomes—the authors explicitly flag this as an area for future research.

That concludes this month's review. The key clinical message: the Veterans Affairs Frailty Index is a robust predictor of overall survival across all melanoma stages, but its relationship to melanoma-specific mortality is stage-dependent, only reaching significance in moderate-to-severely frail patients with stage three or four disease. Surgical treatment remained independently associated with improved survival regardless of frailty status. Thank you for listening, and we'll see you next month.